华大基因：公司高度重视应收账款管理

Core Viewpoint - The company emphasizes the importance of accounts receivable management, which is a common challenge in the industry, and has taken proactive measures to address it [1] Group 1: Accounts Receivable Management - The company reported a credit impairment loss of 116 million yuan for the first half of 2025, attributed to extended payment cycles and decreased payment capabilities of certain clients [1] - A special management team for accounts receivable has been established to implement targeted management strategies based on different client types [1] - The company is closely monitoring policies related to debt restructuring or discounted settlements from local governments concerning public health testing receivables [1] Group 2: Future Outlook - The company expects improvements in cash flow and a reduction in future impairment risks through ongoing collection efforts and the gradual availability of local government funds [1] - The operational efficiency of clients is anticipated to improve, leading to better payment cycles and quality from government and hospital clients, which will help narrow the credit impairment ratio back to normal industry levels [1]